They'll still need to do a P3, from what I've read about...

They'll still need to do a P3, from what I've read about accelerated approvals and still needing to go through the whole clinical trials pathway. For what it's worth, I believe a raise will/should happen irrespective of accelerated approval. I believe, as a company, you don't want to be looking down the barrel of a buyout with little funds., it doesn't allow you to negotiate from a position of strength.

whether for financial leverage or needing funds for a P3, I feel a raise will happen, but not for a long time and hopefully at a significantly higher SP.